← Eichor
Condition: Hodgkin S Disease Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Hodgkin S Disease

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
Phase 2/Phase 3 · 1 location(s) · Children's Cancer Group, China · NCT06563245AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Phase 1 · 13 location(s) · Carna Biosciences, Inc. · NCT05602363Methods of T Cell Depletion Trial (MoTD)
Phase 2 · 17 location(s) · University of Birmingham · NCT04888741Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma
Phase 2 · 1 location(s) · Koo Foundation Sun Yat-Sen Cancer Center · NCT06461182An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treatin
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07101705The "Let's Talk Tech" Tool to Support Decision Making About Technology Use
NA · 1 location(s) · University of Washington · NCT06817122In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT07239323Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Phase 1 · 31 location(s) · Therapeutic Advances in Childhood Leukemia Consortium · NCT05476770A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability,
EARLY_Phase 1 · 4 location(s) · Suzhou Immunofoco Biotechnology Co., Ltd · NCT07376642JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
NA · 1 location(s) · Affiliated Hospital of Guangdong Medical University · NCT06940960A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Phase 2 · 1 location(s) · Ascentage Pharma Group Inc. · NCT04496349Role of Spectral CT in the Evaluation of Cardiotoxicity in Patients With Hodgkin's Lymphoma and Diffuse Large B-cell Lym
Phase N/A · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06774326Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents
Phase 2/Phase 3 · 1 location(s) · Children's Cancer Group, China · NCT07168980Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Phase 2 · 18 location(s) · Canadian Cancer Trials Group · NCT05180097Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07283679Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed
Phase 2 · 6 location(s) · Academic and Community Cancer Research United · NCT06238648A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220
Phase 1 · 26 location(s) · Hoffmann-La Roche · NCT05169515Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Phase 1 · 7 location(s) · Marker Therapeutics, Inc. · NCT05798897CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
Phase 1/Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT02259556An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06693973This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Phase 1 · 6 location(s) · LTZ Therapeutics, Inc. · NCT07121946EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
Phase 1 · 4 location(s) · Baylor College of Medicine · NCT04664179AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Phase 2 · 1 location(s) · Mitchell Cairo · NCT04099966Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Mod
Phase N/A · 8 location(s) · Bristol-Myers Squibb · NCT06357754CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
Phase 2 · 1 location(s) · Shanghai Ming Ju Biotechnology Co., Ltd. · NCT06479356Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy
Phase 1 · 1 location(s) · Michael Randall · NCT06522932A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Ly
Phase 1 · 1 location(s) · Ruijin Hospital · NCT07072169A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic
Phase 1 · 8 location(s) · Autolus Limited · NCT06173518Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Phase 2 · 51 location(s) · Miltenyi Biomedicine GmbH · NCT04844866
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.